Last updated on May 2020

Post Marketing Surveillance on Safety Evaluation of POMALYST (Pomalidomide) Treatment of Multiple Myeloma in Korea


Brief description of study

PMS period: 09Jun2017 ~ 08Jun2023 Target no.: 600patients

indication: POMALYST in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib

The primary objective of this Drug Use Examination (DUE) is to evaluate safety of POMALYST (Pomalidomide) treatment of multiple myeloma in the clinical routine practice in Korea.

The secondary objective of this DUE is to evaluate effectiveness of POMALYST (Pomalidomide) treatment of multiple myeloma in the clinical routine practice in Korea.

Clinical Study Identifier: NCT03288974

Find a site near you

Start Over

Dong-A University Hospital

Busan, Korea, Republic of
  Connect »

Inha University Hospital

Incheon, Korea, Republic of
  Connect »

Severance Hospital

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Ulsan University Hospital

Ulsan, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.